1. Home
  2. URGN vs GIC Comparison

URGN vs GIC Comparison

Compare URGN & GIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • GIC
  • Stock Information
  • Founded
  • URGN 2004
  • GIC 1949
  • Country
  • URGN United States
  • GIC United States
  • Employees
  • URGN N/A
  • GIC N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • GIC Industrial Machinery/Components
  • Sector
  • URGN Health Care
  • GIC Industrials
  • Exchange
  • URGN Nasdaq
  • GIC Nasdaq
  • Market Cap
  • URGN 1.1B
  • GIC 1.3B
  • IPO Year
  • URGN 2017
  • GIC 1995
  • Fundamental
  • Price
  • URGN $27.39
  • GIC $28.26
  • Analyst Decision
  • URGN Strong Buy
  • GIC
  • Analyst Count
  • URGN 8
  • GIC 0
  • Target Price
  • URGN $28.50
  • GIC N/A
  • AVG Volume (30 Days)
  • URGN 1.4M
  • GIC 134.9K
  • Earning Date
  • URGN 11-06-2025
  • GIC 10-28-2025
  • Dividend Yield
  • URGN N/A
  • GIC 3.69%
  • EPS Growth
  • URGN N/A
  • GIC 2.63
  • EPS
  • URGN N/A
  • GIC 1.75
  • Revenue
  • URGN $96,516,000.00
  • GIC $1,335,800,000.00
  • Revenue This Year
  • URGN $35.07
  • GIC $4.26
  • Revenue Next Year
  • URGN $117.83
  • GIC $3.64
  • P/E Ratio
  • URGN N/A
  • GIC $16.06
  • Revenue Growth
  • URGN 8.00
  • GIC 0.16
  • 52 Week Low
  • URGN $3.42
  • GIC $20.79
  • 52 Week High
  • URGN $27.98
  • GIC $38.79
  • Technical
  • Relative Strength Index (RSI)
  • URGN 74.68
  • GIC 41.18
  • Support Level
  • URGN $24.69
  • GIC $26.57
  • Resistance Level
  • URGN $26.28
  • GIC $27.84
  • Average True Range (ATR)
  • URGN 1.87
  • GIC 0.61
  • MACD
  • URGN 0.32
  • GIC 0.35
  • Stochastic Oscillator
  • URGN 95.93
  • GIC 92.82

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About GIC Global Industrial Company

Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw materials.

Share on Social Networks: